2196-56-7 Usage
Uses
Used in Pharmaceutical and Biotechnology Industries:
3-Carboxy-DL-phenylalanine is used as a key component in the production of drugs, leveraging its unique structural properties to contribute to the development of novel therapeutic agents.
Used in Research and Development:
In the realm of research and development, 3-Carboxy-DL-phenylalanine is utilized as a tool for studying the structure-activity relationships of proteins and enzymes, aiding in the advancement of our understanding of biological systems and the design of new bioactive molecules.
Used in the Food and Beverage Industry:
3-Carboxy-DL-phenylalanine is employed to enhance the nutritional content and flavor of food and beverage products, offering a means to improve the quality and appeal of consumables to consumers.
Check Digit Verification of cas no
The CAS Registry Mumber 2196-56-7 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 2,1,9 and 6 respectively; the second part has 2 digits, 5 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 2196-56:
(6*2)+(5*1)+(4*9)+(3*6)+(2*5)+(1*6)=87
87 % 10 = 7
So 2196-56-7 is a valid CAS Registry Number.
InChI:InChI=1/C10H11NO4/c11-8(10(14)15)5-6-2-1-3-7(4-6)9(12)13/h1-4,8H,5,11H2,(H,12,13)(H,14,15)
2196-56-7Relevant academic research and scientific papers
New serine protease inhibitors with leukotriene B4 (LTB4) receptor binding affinity
Nakayama, Yoshisuke,Senokuchi, Kazuhiko,Sakaki, Katsuhito,Kato, Masashi,Maruyama, Toru,Miyazaki, Toru,Ito, Hidenori,Nakai, Hisao,Kawamura, Masanori
, p. 971 - 985 (2007/10/03)
A series of new trypsin-like serine protease inhibitors, 1, 2 and 7-23, containing amidinobenzene moiety was found to show potent LTB4-receptor affinity. Among them, compounds 1 and 2 were found to be LTB4 receptor antagonists based on an inhibition assay of human polymorphonuclear neutrophil (PMN) intracellular calcium mobilization induced by LTB4. Compounds 1 and 2, which satisfy the reported structural requirements for good oral activity, are expected to show a balanced dual mode of action, i.e., protease inhibitory activity and LTB4 receptor antagonist activity, in vivo.
